Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Potential New Obesity Target Found in Mitochondrial Protein Involved in Brown Fat Thermogenesis

Newly reported research in human tissue and in mice has uncovered a mechanism by which brown fat (brown adipose tissue; BAT) is converted into heat, and identified a control protein that may represent a therapeutic target for obesity. The researchers, led by G

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Newly reported research in human tissue and in mice has uncovered a mechanism by which brown fat (brown adipose tissue; BAT) is converted into heat, and identified a control protein that may represent a therapeutic target for obesity. The researchers, led by Guadalupe Sabio, PhD, head of the Organ Crosstalk in Metabolic Diseases Group at the National Cancer Research Centre (CNIO), and Cintia Folgueira, PhD, at CNIO and the National Centre for Cardiovascular Research (CNIC), found that the mechanism is controlled by a mitochondrial protein, methylation-controlled J protein (MCJ). Their experiments showed that when MCJ is removed from obese mice the animals produce more heat and lose weight. The researchers also showed that they could reduce the weight of obese mice by transplanting the animals with fat lacking MCJ.

Reporting on their results in Nature Communications (“Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis”) the team stated, “These findings uncover the importance of MCJ as a regulator of BAT thermogenesis, presenting it as a promising target for obesity therapy.”

Obesity is a global health problem that affects 650 million people worldwide, and predisposes to the development of cardiometabolic diseases, the authors wrote. However, they pointed out, “Despite the societal impact of obesity, understanding the molecular mechanisms and multiple factors through which obesity leads to disease is still limited.”

Obesity is the result of either excessive food intake or inadequate total energy expenditure. Scientists now know that in addition to storing energy, body fat (adipose tissue; AT) plays a crucial role in the management of that energy by the body. “Current knowledge positions AT as a central rheostat in the regulation of systemic nutrient and energy homeostasis,” they stated. “In fact, AT is key to the control of whole-body metabolism and thus, modulating its function likely protects against obesity.”

Of two types of fat in the body, white adipose tissue (WAT) mostly stores energy, while brown adipose tissue—its cells have more mitochondria which gives them a brown hue—is responsible for heat generation, or thermogenesis, the process that maintains body temperature, and which is triggered by cold or other stimuli.

Several studies in the last decade have shown that activating brown fat protects against obesity and metabolic disease. “For some time,” explained Sabio, “it has been thought that obesity could be prevented by getting this fat to spend more energy by generating heat. So, the first thing is to understand how it works.”

“Discovering new mechanisms of heat production in brown fat is one of the most interesting targets in the study of obesity,” said Sabio. For a long time it was thought that brown fat used a single mechanism to generate heat, but today we know that this is not the case. There are several mechanisms involved. The newly reported research has uncovered one mechanism, which they found is controlled by the mitochondrial protein MCJ.

The researchers first identified what they described as reduced MCJ expression in human subcutaneous WAT (WATsc) during obesity, when AT thermogenesis is reduced. “… we show how MCJ expression decreases during obesity, as evident in human and mouse adipose tissue samples,” they wrote. “In parallel, mice fed a high-fat diet (HFD) also displayed decreased MCJ expression in both WATsc and BAT.” In addition, cold exposure resulted in reduced MCJ levels in BAT. These collective findings, the team noted. “… point to a potential role of MCJ in regulating adipose tissue adaptation to obesity in both humans and mice,” they stated.

Their continued work then discovered that when the MCJ protein is removed from BAT in mice, these MCJ knockout (MCJKO) animals fed a high-fat diet (HFD) produced more heat and lost weight when compared with control (wild type; WT) animals, they wrote. “… when exposed to HFD, MCJKO mice showed outcomes distinct from WT control mice. MCJKO mice displayed less weight gain and fat mass accumulation with no discernible alterations in lean mass.” This was associated with increased energy expenditure, they further commented. “Here we found that mice lacking mitochondrial protein MCJ specifically in the BAT exhibited a significant increase in thermogenesis.”

The researchers observed that “… animals without MCJ in brown fat are protected against health problems caused by obesity, such as diabetes or increased blood lipids,” explained the two scientists. They believe that the MCJ protein could be a new therapeutic target to correct diseases associated with obesity. “Collectively, these results affirm that BAT-specific MCJ deficiency enhances BAT temperature and protects against diet-induced obesity,” they stated. “Overall, our work underscores MCJ as a promising candidate for the development of interventions aimed at harnessing the substantial thermogenic potential of BAT to combat obesity and its associated complications.”

CNIO researcher and lead author Beatriz Cicuéndez, PhD, further explained, “This protection is due to the activation of an essential signaling pathway to adapt to the stress caused by obesity. Known as the catabolic pathway, it causes an increase in the consumption of fats, sugars, and proteins to produce heat in brown fat. It is a mechanism that also happens in people with very active brown fat.” In their paper, the team concluded, “Our results in humans and mice suggest that the reduction of MCJ observed in patients with obesity appears to act as a compensatory mechanism to enhance BAT thermogenesis. This adaptation may serve as a protective strategy to counteract excessive weight gain.”

The researchers are now looking to develop a therapy to block this protein in obese patients. However, to do so they will first have to investigate whether the MCJ protein has vital functions in other tissues. At the same time, Sabio said, “We are trying to see if these changes in fat affect tumor growth or cachexia—loss of muscle and fat—which is also sometimes linked to cancer.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →